(S)-2-(3-Methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-(trifluoromethyl)pyrimidin-5-yl)pyridin-2-yl)propanamide
Osteo Arthritis Knee
Eli Lilly and CompanySmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Osteo Arthritis Knee cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Retatrutide Eli Lilly and Company | Phase 3 | BB |
Lopain Sorrento Therapeutics, Inc. | Phase 3 | B |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Sorrento Therapeutics, Inc. | Phase 3 | B |
Naproxen Purdue Pharma LP | Phase 2 | B |
v120083 Purdue Pharma LP | Phase 2 | B |
View all 9 →
Same molecule, other indications
(S)-2-(3-Methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-(trifluoromethyl)pyrimidin-5-yl)pyridin-2-yl)propanamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →